# Inactivating conditions of therapeutic mycobacteriophages

## TL;DR

This study explores conditions that inactivate mycobacteriophages, which are being considered as treatments for drug-resistant mycobacterial infections.

## Contribution

The study identifies specific conditions affecting phage activity and highlights variability among different phages.

## Key findings

- Some conditions caused rapid inactivation of mycobacteriophages.
- Phage-specific differences in sensitivity to inactivating conditions were observed.
- The findings emphasize the need for individual evaluation of therapeutic phages.

## Abstract

There is a need for new therapies to treat drug-resistant nontuberculous mycobacteria (NTM) disease. Bacteriophages (phages), which are viruses that infect and kill bacteria, are actively being explored as an alternative approach for treating mycobacterial diseases. Several compassionate-use cases of phage therapy for drug-resistant NTM infections exhibit favorable outcomes. To further the development of phage therapy, it is important to recognize and avoid conditions that negatively impact phage activity during phage production, storage, formulation, or treatment. Conversely, there is a need to inactivate free phages in certain preclinical phage therapy experiments. In this study, we investigated three mycobacteriophages BPsΔ33HTH-HRM10, Muddy, and ZoeJΔ45 from compassionate-use NTM treatment cases for their sensitivity to a variety of conditions that included temperature, acid pH, detergents, mucus, and phage inactivating buffers. Several conditions resulted in dramatic and rapid reductions in the level of active phage, while others had no effect. We also observed different sensitivities between the phages. The results provide valuable information to support further investigation and development of these phages as therapeutics.

Bacteriophages (phages) offer a promising alternative therapy for treating drug-resistant mycobacterial infections. For the successful implementation of phage therapy, it is important to recognize conditions that inactivate the phages. Here, we studied three mycobacteriophages from recent compassionate-use phage therapy cases for their sensitivity to a range of conditions that may be encountered in production, storage, formulation, or treatment. The results demonstrate sensitivity to some conditions and tolerance to others, and they additionally reveal phage-specific differences in sensitivities, highlighting the need for direct evaluation of individual therapeutic phages during development.